Invivyd, Inc. (IVVD)

Market Cap	53.10M
Revenue (ttm)	11.56M
Net Income (ttm)	-225.14M
Shares Out	119.62M
EPS (ttm)	-1.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,334,411
Open	0.420
Previous Close	0.430
Day's Range	0.404 - 0.453
52-Week Range	0.404 - 5.200
Beta	0.53
Analysts	Strong Buy
Price Target	7.89 (+1,677.43%)
Earnings Date	Nov 14, 2024

About IVVD

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in precl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 95
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://invivyd.com

Analyst Forecast

According to 4 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price forecast is $7.89, which is an increase of 1,677.43% from the latest price.

Price Target

$7.89

(1,677.43% upside)

Analyst Consensus: Strong Buy